Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease
Copenhagen, Denmark, 23rd January 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the Company has been awarded a grant (MJFF-024128) worth c.US$873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease. The project will commence in January 2024 and is led by principal investigators Louise Klem (Senior Research Scientist) and Anders Nykjær (CSO and Founder).
The grant was awarded under the MJFF’s Parkinson’s Disease Therapeutics Pipeline Program (Pre-Clinical). The program seeks to advance preclinical testing of promising therapeutic developments that address unmet medical needs in people with Parkinson’s disease. The program is set up to fund therapeutic development with a clear focus to prevent, stop, or delay disease progression or to reduce the challenges of daily symptoms.
